ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Feb. 11, 2022 (GLOBE NEWSWIRE) -- Molecular Partners AG  (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced that its Chief Executive Officer,

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Jan. 05, 2022 (GLOBE NEWSWIRE) -- Molecular Partners AG  (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced that its Chief Executive Officer,

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Dec. 15, 2021 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced that Senior Management and invited

Program overview and study design for MP0317 to be presented at ESMO Immuno-Oncology Preclinical data supporting novel mechanism of AML candidate MP0533 to be presented at ASH Oncology R&D Day to review cancer therapeutic portfolio and strategy on December 15, 2021 ZURICH-SCHLIEREN, Switzerland and

First presentation of data from patients treated with ensovibep demonstrate the candidate to be safe and well-tolerated All patients exhibited reductions in viral load and complete COVID-19 clinical symptom recovery Additional data presented includes review of the supportive Phase 1 study of

Research collaboration with leading acute myeloid leukemia (AML) experts, Professor Ochsenbein and Professor Riether from the Department of Medical Oncology, Inselspital, Bern University Hospital, Switzerland, to support advancement of drug development process MP0533 is designed to target three

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Nov. 24, 2021 (GLOBE NEWSWIRE) -- Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics, today announced that its Chief Executive Officer,

Second immuno-oncology DARPin candidate to enter the clinic; combines immune stimulation with validated tumor-localizing technology Preclinical data support potential to deliver tumor-localized immune activation while avoiding systemic toxicity seen with other CD40-targeting agents ZURICH